logo
Scientists Discover Secret Weapon That Allows Pythons to Digest Bones

Scientists Discover Secret Weapon That Allows Pythons to Digest Bones

Gizmodo09-07-2025
Pythons are notorious for their eating habits. After suffocating their prey with their lithe bodies, these large snakes swallow the animal whole. Now, researchers have shed new light on the cellular mechanisms that allow them to digest entire skeletons.
The study, presented July 9 at the Society for Experimental Biology Annual Conference in Belgium and published in the Journal of Experimental Biology, investigated the intestinal cells of Burmese pythons. Adult males can grow to be 10 to 16 feet (3 to 5 meters) long, and their impressive size allows them to feed on a wide variety of mammals and birds, including deer and alligators. Unlike other carnivores that only eat flesh, snakes rely on animal skeletons as a calcium source. Absorbing all the available calcium from a skeleton, however, could result in too much of this nutrient entering the serpent's bloodstream. Called hypercalcemia, it can lead to heart conditions, high blood pressure, bone defects, and kidney failure in reptiles.
'We wanted to identify how [pythons] were able to process and limit this huge absorption of calcium through the intestinal wall,' said Jehan-Hervé Lignot, lead author and a professor at the University of Montpellier, in a statement.
To that end, Lignot and his colleagues fed pythons one of three different diets: normal rats, boneless rats, or boneless rats enriched with calcium carbonate to match natural bone calcium levels. One group of snakes did not receive any of these diets and instead fasted for three weeks to provide a baseline. Three to six days post-feeding, the researchers humanely euthanized and dissected the snakes to extract their small intestines.
They then analyzed the enterocytes, or intestinal lining cells, of the pythons using light and electron microscopes alongside measurements of blood calcium and hormone levels. This revealed a never-before-seen type of cell that produces large particles made from calcium, phosphorus, and iron. These particles form structures that Lignot calls 'spheroids.'
'A morphological analysis of the python epithelium revealed specific particles that I'd never seen in other vertebrates,' Lignot said. He and his colleagues found these particles inside the internal 'crypt'—a small pocket or cavity—of specialized cells that differed from traditional intestinal cells. 'Unlike normal absorbing enterocytes, these cells are very narrow, have short microvilli [finger-like membrane protrusions], and have an apical fold that forms a crypt,' he added.
The three different diets that the pythons ate allowed the researchers to assess the function of these unique cells. In snakes that ate boneless prey, the enterocytes did not produce the calcium and phosphorous-rich particles. In those that ate either whole rodents or calcium-supplemented boneless rodents, however, the cells' crypts filled with large particles of calcium, phosphorus, and iron. This suggests that these cells play an important role in breaking down the bones of a python's prey. The researchers found no bones in the snakes' feces, confirming that all skeletons were completely digested and dissolved inside their bodies.
Though it was first identified in Burmese pythons, this new cell type isn't unique to them. Since that initial discovery, the researchers have found these specialized bone-digesting cells in other species of pythons, boas, and the Gila monster, a species of venomous lizard native to the southwestern U.S. and Mexico.
The findings seem to point to an understudied system of mineral regulation in the digestive tracts of reptiles. However, it is possible that this mechanism extends to other types of bone-eating carnivores too, such as sharks and other marine predators, aquatic mammals, or raptors like the bearded vulture, according to Lignot. He told Gizmodo he hopes this work will inspire other researchers to search for these newly discovered cells across the animal kingdom.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Yahoo

time4 minutes ago

  • Yahoo

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1 Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs ZUG, Switzerland, July 17, 2025--(BUSINESS WIRE)--Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1 Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey. "At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission." FLEMMING ØRNSKOV, M.D., MPHCHIEF EXECUTIVE OFFICERGALDERMA In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment.1 Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT:1 The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 91 Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9:1 85.7% of patients said their face looked less gaunt/sunken1 88.6% said they "loved" how the treatment maintained their facial structure1 88.6% of patients said they "loved" the regenerative effects of Sculptra treatment1 88.6% felt they looked better than before the injection regimen1 91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin1 Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports.1 "The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel." Z. PAUL LORENC, TRIAL INVESTIGATORNEW YORK, UNITED STATES "These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care." MICHAEL SOMENEK, TRIAL INVESTIGATORWASHINGTON DC, UNITED STATES Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report.5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey.6 *Restylane Contour is known as Restylane® Volyme™ in countries outside of the U.S. About the studyThis phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1 About GaldermaGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results. Mansour MR, et al. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/ Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/ Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321 Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. View source version on Contacts Christian Marcoux, Communications +41 76 315 26 50 Richard HarbinsonCorporate Communications +41 76 210 60 62 Céline BuguetFranchises and R&D Communications +41 76 249 90 87 Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12 Jessica CohenInvestor Relations and Strategy +41 21 642 76 43

Food Allergies Alter Nutrient Intake in Adults
Food Allergies Alter Nutrient Intake in Adults

Medscape

time5 minutes ago

  • Medscape

Food Allergies Alter Nutrient Intake in Adults

TOPLINE: Adults with milk or egg allergies and those with a combination of milk/egg and peanut or tree nut allergies had significantly lower intake of cholesterol, short-chain fatty acids (SCFAs), and medium-chain (MC) FAs than the general population. The mixed allergy group also consumed more fiber, genistein, and daidzein. METHODOLOGY: Researchers compared intakes of nutrients and food compounds between Dutch adults aged 19 years or older with confirmed food allergies (n = 73; 70% women) and matched control individuals of the same age range (n = 415; 64% women). Adults with allergies were categorized as those with milk/egg allergy (n = 16), peanut/tree nut allergy (n = 35), and combined milk/egg and peanut/tree nut allergies, also referred to as mixed allergy (n = 22). Dietary intake was assessed using structured 24-hour recalls on 2 nonconsecutive days (1 weekday and 1 weekend day). TAKEAWAY: Intakes of beta-lactose, butyric acid, caproic acid, capric acid, caprylic acid, lauric acid, myristoleic acid, conjugated linoleic acid, and unspecified saturated fatty acids were significantly lower in the milk/egg and mixed allergy groups than the general population, with 1.6-3.2 and 1.3-2.9 lower mean defined intake levels, respectively. The combined allergy group had 1.7-1.8 times higher consumption of several bell pepper compounds (primarily capsianosides and capsaicinoids) than the general population. The milk/egg allergy group had 4.6-4.7 times higher intakes of soy polyphenols (daidzein and genistein) than the general population. The intake of food compounds was not significantly different between the peanut/tree nut allergy group and general population. IN PRACTICE: 'Notably, milk/egg and mixed allergic individuals showed a significantly lower intake of SCFA and MCFA that are presumed to play a beneficial role in the human body, including intestinal health. The low intake of these fatty acids may therefore potentially negatively affect their health,' the authors wrote. 'On the other hand, lower cholesterol and higher total fiber, genistein, and daidzein intakes in the mixed allergic group might provide a health benefit over the general population.' SOURCE: Marie Y. Meima, with University Medical Center Utrecht, Utrecht, the Netherlands, was the corresponding author of the study, which was published online on July 11 in Nutrients. LIMITATIONS: The study was potentially limited by the small sample size of the allergy groups, absence of data on supplement use, and coverage of only 489 food compounds, which represents just a fraction of the tens of thousands of compounds present in the diet. DISCLOSURES: This study was funded by Dutch Governmental TNO Research Cooperation Funds. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store